I don't think most people are nostalgic for this a
Post# of 72447
(Total Views: 312)
Posted On: 07/17/2017 9:14:45 PM
I don't think most people are nostalgic for this article. I'd call it a comedy of bad predictions if it wasn't so tragic.
Look at some of the gems from that article:
This was in May 2011 folks. Pharmasset was bought out six months later for $11 billion. I'm sure this author is thrilled he put dollars into CTIX instead of VRUS. I'm sure some of the folks on this board are too.
It was a piece that name dropped VRUS at the height of it's results frenzy. The CTIX stock price was around $0.90 in 2011 when this was written - similar prices to what we're offered today in 2017. When you consider that he NASDAQ index has more than doubled since this article was published it hurts even more. This article hit anyone who invested in CTIX at the time with quite the opportunity cost.
This author dangled a fast track "jump staight into phase 3" after a "very minimal" time in phase 1. In reality it took almost six years from the publishing of this article to initiate our first Phase 2A for Kevetrin. Talk about getting your timing wrong.
It's also instructive that your favorite article on Kevetrin to date was published over six years ago prior to IND. You've probably done more digging on this company and the ecosystem than most. That you haven't found a new favorite since then speaks volumes as to why there is little market excitement surrounding Kevetrin at this time.
Of all the exciting things we have brewing you dusted this article off? It's a nice overview of Kevetrin but some of these predictions were worse than 80's fashion.
Go IPIX!
Look at some of the gems from that article:
Quote:
may actually leave me owing Pharmasset a debt of gratitude as it is theoretically possible that Cellceutix will leapfrog past Pharmasset’s lead compound in the overall FDA approval process in the next 18 months.
This was in May 2011 folks. Pharmasset was bought out six months later for $11 billion. I'm sure this author is thrilled he put dollars into CTIX instead of VRUS. I'm sure some of the folks on this board are too.
Quote:
Even though KevetrinTM is addressing a much larger target population and potential revenue would far exceed a $3.75 billion market cap (market cap is typically valued at 4 to 5 times potential sales), a valuation comparable to Phamasset’s market cap would place the cost of a share of Cellceutix around $42.
It was a piece that name dropped VRUS at the height of it's results frenzy. The CTIX stock price was around $0.90 in 2011 when this was written - similar prices to what we're offered today in 2017. When you consider that he NASDAQ index has more than doubled since this article was published it hurts even more. This article hit anyone who invested in CTIX at the time with quite the opportunity cost.
Quote:
The “Accelerated Approval” and “Priority Review” programs are exactly what Cellceutix will be focused upon should efficacy should be demonstrated which could literally mean a jump straight to Phase III clinical trials after a very minimal time in Phase I..
This author dangled a fast track "jump staight into phase 3" after a "very minimal" time in phase 1. In reality it took almost six years from the publishing of this article to initiate our first Phase 2A for Kevetrin. Talk about getting your timing wrong.
It's also instructive that your favorite article on Kevetrin to date was published over six years ago prior to IND. You've probably done more digging on this company and the ecosystem than most. That you haven't found a new favorite since then speaks volumes as to why there is little market excitement surrounding Kevetrin at this time.
Of all the exciting things we have brewing you dusted this article off? It's a nice overview of Kevetrin but some of these predictions were worse than 80's fashion.
Go IPIX!
(2)
(0)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
All my posts are my own personal opinion and speculation. They should not be used as the basis for any investment decision. No, I am not Scottsmith.